{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T17:13:48Z","timestamp":1788542028786,"version":"build-2803163510"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40262-026-01691-9","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:02:03Z","timestamp":1787313723000},"page":"1317-1337","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacokinetics, Safety, and Dosing of Antiseizure Medications in Patients with Renal or Hepatic Impairment"],"prefix":"10.1007","volume":"65","author":[{"given":"Jingheng","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaomiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4589-571X","authenticated-orcid":false,"given":"Shuai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"key":"1691_CR1","doi-asserted-by":"publisher","unstructured":"Global, regional, and national burden of epilepsy, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(4):357\u201375. https:\/\/doi.org\/10.1016\/s1474-4422(18)30454-x","DOI":"10.1016\/s1474-4422(18)30454-x"},{"issue":"5","key":"1691_CR2","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1056\/nejm200002033420503","volume":"342","author":"P Kwan","year":"2000","unstructured":"Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000;342(5):314\u20139. https:\/\/doi.org\/10.1056\/nejm200002033420503.","journal-title":"N Engl J Med"},{"issue":"9","key":"1691_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2021.105651","volume":"30","author":"M Sazgar","year":"2021","unstructured":"Sazgar M. Kidney disease and epilepsy. J Stroke Cerebrovasc Dis. 2021;30(9):105651. https:\/\/doi.org\/10.1016\/j.jstrokecerebrovasdis.2021.105651.","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"1691_CR4","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.seizure.2020.02.006","volume":"76","author":"SH Mahmoud","year":"2020","unstructured":"Mahmoud SH, Zhou XY, Ahmed SN. Managing the patient with epilepsy and renal impairment. Seizure. 2020;76:143\u201352. https:\/\/doi.org\/10.1016\/j.seizure.2020.02.006.","journal-title":"Seizure"},{"issue":"5","key":"1691_CR5","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1016\/j.kint.2019.04.033","volume":"96","author":"SP Waddy","year":"2019","unstructured":"Waddy SP, Ward JB, Becerra AZ, Powers T, Fwu CW, Williams KL, et al. Epilepsy and antiseizure medications increase all-cause mortality in dialysis patients in the United States. Kidney Int. 2019;96(5):1176\u201384. https:\/\/doi.org\/10.1016\/j.kint.2019.04.033.","journal-title":"Kidney Int"},{"key":"1691_CR6","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/b978-0-7020-4086-3.00027-8","volume":"119","author":"JJ Asconap\u00e9","year":"2014","unstructured":"Asconap\u00e9 JJ. Use of antiepileptic drugs in hepatic and renal disease. Handb Clin Neurol. 2014;119:417\u201332. https:\/\/doi.org\/10.1016\/b978-0-7020-4086-3.00027-8.","journal-title":"Handb Clin Neurol"},{"issue":"7","key":"1691_CR7","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1111\/epi.14442","volume":"59","author":"AM Alkhachroum","year":"2018","unstructured":"Alkhachroum AM, Rubinos C, Kummer BR, Parikh NS, Chen M, Chatterjee A, et al. Risk of seizures and status epilepticus in older patients with liver disease. Epilepsia. 2018;59(7):1392\u20137. https:\/\/doi.org\/10.1111\/epi.14442.","journal-title":"Epilepsia"},{"issue":"12","key":"1691_CR8","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s00228-008-0553-z","volume":"64","author":"RK Verbeeck","year":"2008","unstructured":"Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol. 2008;64(12):1147\u201361. https:\/\/doi.org\/10.1007\/s00228-008-0553-z.","journal-title":"Eur J Clin Pharmacol"},{"issue":"8","key":"1691_CR9","doi-asserted-by":"publisher","first-page":"879","DOI":"10.2174\/011570159x323666241029171256","volume":"23","author":"YH Ng","year":"2025","unstructured":"Ng YH, Jamil SNH, Sarian MN, Ahmed QU, Latip J, Lam SD, et al. Antiseizure medications: advancements, challenges, and prospects in drug development. Curr Neuropharmacol. 2025;23(8):879\u2013906. https:\/\/doi.org\/10.2174\/011570159x323666241029171256.","journal-title":"Curr Neuropharmacol"},{"issue":"1","key":"1691_CR10","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1212\/cont.0000000000001521","volume":"31","author":"BW Abou-Khalil","year":"2025","unstructured":"Abou-Khalil BW. Update on antiseizure medications 2025. Continuum. 2025;31(1):125\u201364. https:\/\/doi.org\/10.1212\/cont.0000000000001521.","journal-title":"Continuum"},{"key":"1691_CR11","unstructured":"U.S. Food and Drug Administration. Fycompa (perampanel) [package insert]. U.S. Prescribing Information. Silver Spring, MD: U.S. Food and Drug Administration; 2023. Available from: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=ec812ea3-de3a-4271-957c-db8f692d1ae3"},{"key":"1691_CR12","unstructured":"European Medicines Agency. Fycompa (perampanel): Summary of Product Characteristics. Amsterdam: European Medicines Agency; 2024. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/fycompa"},{"key":"1691_CR13","unstructured":"U.S. Food and Drug Administration. Fintepla (fenfluramine) [package insert]. U.S. Prescribing Information. Silver Spring, MD: U.S. Food and Drug Administration; 2024. Available from: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=e88f360e-33ad-4cd6-b2de-5ef885857c5d"},{"key":"1691_CR14","unstructured":"European Medicines Agency. Fintepla (fenfluramine): Summary of Product Characteristics. Amsterdam: European Medicines Agency; 2024. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/fintepla"},{"issue":"4","key":"1691_CR15","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1111\/sdi.12385","volume":"28","author":"AD Bansal","year":"2015","unstructured":"Bansal AD, Hill CE, Berns JS. Use of antiepileptic drugs in patients with chronic kidney disease and end stage renal disease. Semin Dial. 2015;28(4):404\u201312. https:\/\/doi.org\/10.1111\/sdi.12385.","journal-title":"Semin Dial"},{"issue":"10","key":"1691_CR16","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/nrd4126","volume":"12","author":"W L\u00f6scher","year":"2013","unstructured":"L\u00f6scher W, Klitgaard H, Twyman RE, Schmidt D. New avenues for anti-epileptic drug discovery and development. Nat Rev Drug Discov. 2013;12(10):757\u201376. https:\/\/doi.org\/10.1038\/nrd4126.","journal-title":"Nat Rev Drug Discov"},{"key":"1691_CR17","unstructured":"U.S. Food and Drug Administration. Guidance for Industry: Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling. Silver Spring, MD: U.S. Food and Drug Administration; 2003. Available from: https:\/\/www.fda.gov\/media\/71311\/download"},{"key":"1691_CR18","unstructured":"U.S. Food and Drug Administration. Guidance for Industry: Pharmacokinetics in Patients with Impaired Renal Function: Study Design, Data Analysis, and Impact on Dosing. Silver Spring, MD: U.S. Food and Drug Administration; 2024. Available from: https:\/\/www.fda.gov\/media\/78573\/download"},{"issue":"8","key":"1691_CR19","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s00228-009-0678-8","volume":"65","author":"RK Verbeeck","year":"2009","unstructured":"Verbeeck RK, Musuamba FT. Pharmacokinetics and dosage adjustment in patients with renal dysfunction. Eur J Clin Pharmacol. 2009;65(8):757\u201373. https:\/\/doi.org\/10.1007\/s00228-009-0678-8.","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"1691_CR20","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.ajkd.2003.07.019","volume":"42","author":"TD Nolin","year":"2003","unstructured":"Nolin TD, Frye RF, Matzke GR. Hepatic drug metabolism and transport in patients with kidney disease. Am J Kidney Dis. 2003;42(5):906\u201325. https:\/\/doi.org\/10.1016\/j.ajkd.2003.07.019.","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"1691_CR21","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1038\/clpt.2008.59","volume":"83","author":"TD Nolin","year":"2008","unstructured":"Nolin TD, Naud J, Leblond FA, Pichette V. Emerging evidence of the impact of kidney disease on drug metabolism and transport. Clin Pharmacol Ther. 2008;83(6):898\u2013903. https:\/\/doi.org\/10.1038\/clpt.2008.59.","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"1691_CR22","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1111\/epi.13802","volume":"58","author":"PN Patsalos","year":"2017","unstructured":"Patsalos PN, Zugman M, Lake C, James A, Ratnaraj N, Sander JW. Serum protein binding of 25 antiepileptic drugs in a routine clinical setting: a comparison of free non-protein-bound concentrations. Epilepsia. 2017;58(7):1234\u201343. https:\/\/doi.org\/10.1111\/epi.13802.","journal-title":"Epilepsia"},{"issue":"7","key":"1691_CR23","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","volume":"49","author":"PN Patsalos","year":"2008","unstructured":"Patsalos PN, Berry DJ, Bourgeois BF, Cloyd JC, Glauser TA, Johannessen SI, et al. Antiepileptic drugs\u2013best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE commission on therapeutic strategies. Epilepsia. 2008;49(7):1239\u201376. https:\/\/doi.org\/10.1111\/j.1528-1167.2008.01561.x.","journal-title":"Epilepsia"},{"issue":"3","key":"1691_CR24","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.clpt.2006.05.006","volume":"80","author":"RF Frye","year":"2006","unstructured":"Frye RF, Zgheib NK, Matzke GR, Chaves-Gnecco D, Rabinovitz M, Shaikh OS, et al. Liver disease selectively modulates cytochrome P450\u2013mediated metabolism. Clin Pharmacol Ther. 2006;80(3):235\u201345. https:\/\/doi.org\/10.1016\/j.clpt.2006.05.006.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"1691_CR25","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.3748\/wjg.v22.i3.1260","volume":"22","author":"P Palatini","year":"2016","unstructured":"Palatini P, De Martin S. Pharmacokinetic drug interactions in liver disease: an update. World J Gastroenterol. 2016;22(3):1260\u201378. https:\/\/doi.org\/10.3748\/wjg.v22.i3.1260.","journal-title":"World J Gastroenterol"},{"issue":"5","key":"1691_CR26","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1097\/ftd.0000000000000546","volume":"40","author":"PN Patsalos","year":"2018","unstructured":"Patsalos PN, Spencer EP, Berry DJ. Therapeutic drug monitoring of antiepileptic drugs in epilepsy: a 2018 update. Ther Drug Monit. 2018;40(5):526\u201348. https:\/\/doi.org\/10.1097\/ftd.0000000000000546.","journal-title":"Ther Drug Monit"},{"key":"1691_CR27","unstructured":"U.S. Food and Drug Administration. Vimpat (lacosamide) [package insert]. U.S. Prescribing Information. Silver Spring, MD: U.S. Food and Drug Administration; 2023. Available from: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=9e79b42c-38a3-4b2c-a196-a5a1948250e2"},{"key":"1691_CR28","unstructured":"European Medicines Agency. Vimpat (lacosamide): Summary of Product Characteristics. Amsterdam: European Medicines Agency; 2024. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vimpat"},{"issue":"10","key":"1691_CR29","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s40262-013-0080-7","volume":"52","author":"W Cawello","year":"2013","unstructured":"Cawello W, Fuhr U, Hering U, Maatouk H, Halabi A. Impact of impaired renal function on the pharmacokinetics of the antiepileptic drug lacosamide. Clin Pharmacokinet. 2013;52(10):897\u2013906. https:\/\/doi.org\/10.1007\/s40262-013-0080-7.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"1691_CR30","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1177\/0897190018803765","volume":"33","author":"PM Wieruszewski","year":"2020","unstructured":"Wieruszewski PM, Lopez-Ruiz A, Albright RC, Fugate JE, Barreto EF. Lacosamide pharmacokinetics in a critically ill patient during continuous renal replacement therapy. J Pharm Pract. 2020;33(3):395\u20138. https:\/\/doi.org\/10.1177\/0897190018803765.","journal-title":"J Pharm Pract"},{"issue":"2","key":"1691_CR31","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1002\/phar.2063","volume":"38","author":"MJ Franquiz","year":"2018","unstructured":"Franquiz MJ, Kalaria SN, Armahizer MJ, Gopalakrishnan M, McCarthy PJ, Badjatia N. Lacosamide pharmacokinetics in a critically ill patient receiving continuous venovenous hemofiltration. Pharmacotherapy. 2018;38(2):e17\u201321. https:\/\/doi.org\/10.1002\/phar.2063.","journal-title":"Pharmacotherapy"},{"issue":"11","key":"1691_CR32","doi-asserted-by":"publisher","first-page":"4375","DOI":"10.1111\/bcp.14858","volume":"87","author":"SN Kalaria","year":"2021","unstructured":"Kalaria SN, Armahizer M, McCarthy P, Badjatia N, Gobburu JV, Gopalakrishnan M. A prospective, real-world, clinical pharmacokinetic study to inform lacosamide dosing in critically ill patients undergoing continuous venovenous haemofiltration (PADRE-02). Br J Clin Pharmacol. 2021;87(11):4375\u201385. https:\/\/doi.org\/10.1111\/bcp.14858.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"1691_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s40560-023-00700-4","volume":"11","author":"W Chaijamorn","year":"2023","unstructured":"Chaijamorn W, Phunpon S, Sathienluckana T, Charoensareerat T, Pattharachayakul S, Rungkitwattanakul D, et al. Lacosamide dosing in patients receiving continuous renal replacement therapy. J Intensive Care. 2023;11(1):50. https:\/\/doi.org\/10.1186\/s40560-023-00700-4.","journal-title":"J Intensive Care"},{"issue":"1","key":"1691_CR34","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-024-05897-6","volume":"184","author":"T Zhao","year":"2024","unstructured":"Zhao T, Li HJ, Zhang HL, Yu J, Feng J, Cui L, et al. Effects of CYP2C19 and CYP2C9 polymorphisms on the efficacy and plasma concentration of lacosamide in pediatric patients with epilepsy in China. Eur J Pediatr. 2024;184(1):73. https:\/\/doi.org\/10.1007\/s00431-024-05897-6.","journal-title":"Eur J Pediatr"},{"issue":"6","key":"1691_CR35","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1111\/j.1528-1167.2012.03519.x","volume":"53","author":"M Bialer","year":"2012","unstructured":"Bialer M, Soares-da-Silva P. Pharmacokinetics and drug interactions of eslicarbazepine acetate. Epilepsia. 2012;53(6):935\u201346. https:\/\/doi.org\/10.1111\/j.1528-1167.2012.03519.x.","journal-title":"Epilepsia"},{"issue":"9","key":"1691_CR36","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1177\/0091270005279364","volume":"45","author":"L Almeida","year":"2005","unstructured":"Almeida L, Falc\u00e3o A, Maia J, Mazur D, Gellert M, Soares-da-Silva P. Single-dose and steady-state pharmacokinetics of eslicarbazepine acetate (BIA 2-093) in healthy elderly and young subjects. J Clin Pharmacol. 2005;45(9):1062\u20136. https:\/\/doi.org\/10.1177\/0091270005279364.","journal-title":"J Clin Pharmacol"},{"key":"1691_CR37","unstructured":"U.S. Food and Drug Administration. Aptiom (eslicarbazepine acetate) [package insert]. U.S. Prescribing Information. Silver Spring, MD: U.S. Food and Drug Administration; 2023. Available from: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=3d0c9554-eaeb-4694-8089-00133fcadce3"},{"key":"1691_CR38","unstructured":"European Medicines Agency. Zebinix (eslicarbazepine acetate): Summary of Product Characteristics. Summary of Product Characteristics. Amsterdam: European Medicines Agency; 2024. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zebinix"},{"issue":"3","key":"1691_CR39","doi-asserted-by":"publisher","first-page":"119","DOI":"10.5414\/cpp46119","volume":"46","author":"J Maia","year":"2008","unstructured":"Maia J, Almeida L, Falcao A, Soares E, Mota F, Potgieter MA, et al. Effect of renal impairment on the pharmacokinetics of eslicarbazepine acetate. Int J Clin Pharmacol Ther. 2008;46(3):119\u201330. https:\/\/doi.org\/10.5414\/cpp46119.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"3","key":"1691_CR40","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00228-007-0414-1","volume":"64","author":"L Almeida","year":"2008","unstructured":"Almeida L, Potgieter JH, Maia J, Potgieter MA, Mota F, Soares-da-Silva P. Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment. Eur J Clin Pharmacol. 2008;64(3):267\u201373. https:\/\/doi.org\/10.1007\/s00228-007-0414-1.","journal-title":"Eur J Clin Pharmacol"},{"key":"1691_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/cpaa.S114072","volume":"10","author":"P Klein","year":"2018","unstructured":"Klein P, Diaz A, Gasalla T, Whitesides J. A review of the pharmacology and clinical efficacy of brivaracetam. Clin Pharmacol. 2018;10:1\u201322. https:\/\/doi.org\/10.2147\/cpaa.S114072.","journal-title":"Clin Pharmacol"},{"key":"1691_CR42","unstructured":"U.S. Food and Drug Administration. Briviact (brivaracetam) [package insert]. U.S. Prescribing Information. Silver Spring, MD: U.S. Food and Drug Administration; 2023. Available from: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=3cf2f439-0e97-443e-8e33-25ecef616f6c"},{"key":"1691_CR43","unstructured":"European Medicines Agency. Briviact (brivaracetam): Summary of Product Characteristics. Amsterdam: European Medicines Agency; 2024. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/briviact-italy-nubriveo"},{"issue":"7","key":"1691_CR44","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s40263-025-01178-4","volume":"39","author":"T Nie","year":"2025","unstructured":"Nie T, Hoy SM. Cenobamate: A Review in Focal-Onset Seizures. CNS Drugs. 2025;39(7):707\u201319. https:\/\/doi.org\/10.1007\/s40263-025-01178-4.","journal-title":"CNS Drugs"},{"key":"1691_CR45","unstructured":"U.S. Food and Drug Administration. Xcopri (cenobamate) [package insert]. U.S. Prescribing Information. Silver Spring, MD: U.S. Food and Drug Administration; 2024. Available from: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=565c2126-57ae-4e29-b443-723bbe7e2072"},{"issue":"4","key":"1691_CR46","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1111\/cts.13204","volume":"15","author":"SA Greene","year":"2022","unstructured":"Greene SA, Kwak C, Kamin M, Vernillet L, Glenn KJ, Gabriel L, et al. Effect of cenobamate on the single-dose pharmacokinetics of multiple cytochrome P450 probes using a cocktail approach in healthy subjects. Clin Transl Sci. 2022;15(4):899\u2013911. https:\/\/doi.org\/10.1111\/cts.13204.","journal-title":"Clin Transl Sci"},{"key":"1691_CR47","unstructured":"European Medicines Agency. Ontozry (cenobamate): Summary of Product Characteristics. Amsterdam: European Medicines Agency; 2024. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ontozry"},{"issue":"4","key":"1691_CR48","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1002\/epi4.12996","volume":"9","author":"Y Nakazawa","year":"2024","unstructured":"Nakazawa Y, Shiraishi W, Matsuyoshi A, Inamori Y, Mitani K, Ando N, et al. Serum perampanel levels in patients with seizures are not affected by hemodialysis. Epilepsia Open. 2024;9(4):1597\u2013603. https:\/\/doi.org\/10.1002\/epi4.12996.","journal-title":"Epilepsia Open"},{"issue":"1","key":"1691_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-018-0221-6","volume":"19","author":"H Molanaei","year":"2018","unstructured":"Molanaei H, Qureshi AR, Heimburger O, Lindholm B, Diczfalusy U, Anderstam B, et al. Inflammation down-regulates CYP3A4-catalysed drug metabolism in hemodialysis patients. BMC Pharmacol Toxicol. 2018;19(1):33. https:\/\/doi.org\/10.1186\/s40360-018-0221-6.","journal-title":"BMC Pharmacol Toxicol"},{"issue":"12","key":"1691_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/genes11121509","volume":"11","author":"LM de Jong","year":"2020","unstructured":"de Jong LM, Jiskoot W, Swen JJ, Manson ML. Distinct effects of inflammation on cytochrome P450 regulation and drug metabolism: lessons from experimental models and a potential role for pharmacogenetics. Genes (Basel). 2020;11(12):1509. https:\/\/doi.org\/10.3390\/genes11121509.","journal-title":"Genes (Basel)"},{"issue":"6","key":"1691_CR51","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1097\/ftd.0000000000000556","volume":"40","author":"Y Yamamoto","year":"2018","unstructured":"Yamamoto Y, Takahashi Y, Horino A, Usui N, Nishida T, Imai K, et al. Influence of inflammation on the pharmacokinetics of perampanel. Ther Drug Monit. 2018;40(6):725\u20139. https:\/\/doi.org\/10.1097\/ftd.0000000000000556.","journal-title":"Ther Drug Monit"},{"key":"1691_CR52","doi-asserted-by":"publisher","first-page":"9844820","DOI":"10.1155\/2022\/9844820","volume":"2022","author":"Y Kinoshita","year":"2022","unstructured":"Kinoshita Y, Ueno H, Kurata H, Ikeda C, Hori E, Okada T, et al. Infection-induced elevated plasma Perampanel in a patient with Hemimegalencephaly. Case Rep Pediatr. 2022;2022:9844820. https:\/\/doi.org\/10.1155\/2022\/9844820.","journal-title":"Case Rep Pediatr."},{"issue":"2","key":"1691_CR53","doi-asserted-by":"publisher","first-page":"256","DOI":"10.5863\/jppt-25-00087","volume":"31","author":"S Meguro","year":"2026","unstructured":"Meguro S, Imai T, Ishii W, Momoki E, Kawaguchi T, Matsuda K, et al. Elevated serum concentrations of Lacosamide and Perampanel in a Pediatric patient following coadministration of clarithromycin for Mycoplasma pneumoniae Pneumonia. J Pediatr Pharmacol Ther. 2026;31(2):256\u201361. https:\/\/doi.org\/10.5863\/jppt-25-00087.","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"23","key":"1691_CR54","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1161\/01.cir.102.23.2836","volume":"102","author":"RB Rothman","year":"2000","unstructured":"Rothman RB, Baumann MH, Savage JE, Rauser L, McBride A, Hufeisen SJ, et al. Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation. 2000;102(23):2836\u201341. https:\/\/doi.org\/10.1161\/01.cir.102.23.2836.","journal-title":"Circulation"},{"issue":"3","key":"1691_CR55","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.958","volume":"10","author":"P Martin","year":"2022","unstructured":"Martin P, Czerwinski M, Limaye PB, Muranjan S, Ogilvie BW, Smith S, et al. In vitro evaluation of fenfluramine and norfenfluramine as victims of drug interactions. Pharmacol Res Perspect. 2022;10(3):e00958. https:\/\/doi.org\/10.1002\/prp2.958.","journal-title":"Pharmacol Res Perspect"},{"key":"1691_CR56","unstructured":"U.S. Food and Drug Administration. Ztalmy (ganaxolone) [package insert]. U.S. Prescribing Information. Silver Spring, MD: U.S. Food and Drug Administration; 2022. Available from: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=d91612c4-b03a-4be4-a1ee-6a13e3b83d4e"},{"key":"1691_CR57","unstructured":"European Medicines Agency. Ztalmy (ganaxolone): Summary of Product Characteristics. Amsterdam: European Medicines Agency; 2023. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ztalmy"},{"key":"1691_CR58","unstructured":"U.S. Food and Drug Administration. Epidiolex (cannabidiol) [package insert]. U.S. Prescribing Information. Silver Spring, MD: U.S. Food and Drug Administration; 2023. Available from: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=8bf27097-4870-43fb-94f0-f3d0871d1eec"},{"key":"1691_CR59","unstructured":"European Medicines Agency. Epidyolex (cannabidiol): Summary of Product Characteristics. Amsterdam: European Medicines Agency; 2024. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/epidyolex"},{"issue":"8","key":"1691_CR60","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1002\/jcph.1412","volume":"59","author":"L Taylor","year":"2019","unstructured":"Taylor L, Crockett J, Tayo B, Morrison G. A phase 1, open-label, parallel-group, single-dose trial of the pharmacokinetics and safety of cannabidiol (CBD) in subjects with mild to severe hepatic impairment. J Clin Pharmacol. 2019;59(8):1110\u20139. https:\/\/doi.org\/10.1002\/jcph.1412.","journal-title":"J Clin Pharmacol"},{"key":"1691_CR61","unstructured":"U.S. Food and Drug Administration. Diacomit (stiripentol) [package insert]. U.S. Prescribing Information. Silver Spring, MD: U.S. Food and Drug Administration; 2023. Available from: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=58304ba8-9779-4658-811e-94ffe08c3f16"},{"key":"1691_CR62","unstructured":"European Medicines Agency. Diacomit (stiripentol): Summary of Product Characteristics. Amsterdam: European Medicines Agency; 2024. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/diacomit"},{"issue":"5","key":"1691_CR63","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/s0009-9236(97)90044-8","volume":"62","author":"A Tran","year":"1997","unstructured":"Tran A, Rey E, Pons G, Rousseau M, d\u2019Athis P, Olive G, et al. Influence of stiripentol on cytochrome P450-mediated metabolic pathways in humans: in vitro and in vivo comparison and calculation of in vivo inhibition constants. Clin Pharmacol Ther. 1997;62(5):490\u2013504. https:\/\/doi.org\/10.1016\/s0009-9236(97)90044-8.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"1691_CR64","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1124\/dmd.105.007237","volume":"34","author":"C Giraud","year":"2006","unstructured":"Giraud C, Treluyer JM, Rey E, Chiron C, Vincent J, Pons G, et al. In vitro and in vivo inhibitory effect of stiripentol on clobazam metabolism. Drug Metab Dispos. 2006;34(4):608\u201311. https:\/\/doi.org\/10.1124\/dmd.105.007237.","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"1691_CR65","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1002\/epi4.12847","volume":"9","author":"A Gil-Nagel","year":"2024","unstructured":"Gil-Nagel A, Aledo-Serrano A, Beltran-Corbellini A, Martinez-Vicente L, Jimenez-Huete A, Toledano-Delgado R, et al. Efficacy and tolerability of add-on stiripentol in real-world clinical practice: an observational study in Dravet syndrome and non-Dravet developmental and epileptic encephalopathies. Epilepsia Open. 2024;9(1):164\u201375. https:\/\/doi.org\/10.1002\/epi4.12847.","journal-title":"Epilepsia Open"},{"issue":"3","key":"1691_CR66","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s40801-022-00305-7","volume":"9","author":"S Balestrini","year":"2022","unstructured":"Balestrini S, Doccini V, Boncristiano A, Lenge M, De Masi S, Guerrini R. Efficacy and safety of long-term treatment with stiripentol in children and adults with drug-resistant epilepsies: a retrospective cohort study of 196 patients. Drugs Real World Outcomes. 2022;9(3):451\u201361. https:\/\/doi.org\/10.1007\/s40801-022-00305-7.","journal-title":"Drugs Real World Outcomes"},{"issue":"2","key":"1691_CR67","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2515\/therapie\/2012014","volume":"67","author":"MC Verdier","year":"2012","unstructured":"Verdier MC, Tribut O, Bentue-Ferrer D. Therapeutic drug monitoring of stiripentol. Therapie. 2012;67(2):157\u201360. https:\/\/doi.org\/10.2515\/therapie\/2012014.","journal-title":"Therapie"},{"issue":"11","key":"1691_CR68","doi-asserted-by":"publisher","DOI":"10.3390\/jpm15110549","volume":"15","author":"B Eltanameli","year":"2025","unstructured":"Eltanameli B, Al Sahlawi S, Cristofoletti R. Physiologically based pharmacokinetic modeling of clobazam and stiripentol co-therapy in Dravet syndrome. J Pers Med. 2025;15(11):549. https:\/\/doi.org\/10.3390\/jpm15110549.","journal-title":"J Pers Med"},{"issue":"3","key":"1691_CR69","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1097\/ftd.0000000000000272","volume":"38","author":"ML Burns","year":"2016","unstructured":"Burns ML, Baftiu A, Opdal MS, Johannessen SI, Landmark CJ. Therapeutic drug monitoring of clobazam and its metabolite-impact of age and comedication on pharmacokinetic variability. Ther Drug Monit. 2016;38(3):350\u20137. https:\/\/doi.org\/10.1097\/ftd.0000000000000272.","journal-title":"Ther Drug Monit"},{"key":"1691_CR70","unstructured":"U.S. Food and Drug Administration. Banzel (rufinamide) [package insert]. U.S. Prescribing Information. Silver Spring, MD: U.S. Food and Drug Administration; 2023. Available from: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=0a3fa925-1abd-458a-bd57-4ae780a1ef2d"},{"key":"1691_CR71","unstructured":"European Medicines Agency. Inovelon (rufinamide): Summary of Product Characteristics. Amsterdam: European Medicines Agency; 2024. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/inovelon"},{"issue":"1","key":"1691_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1535-7511.2009.01336.x","volume":"10","author":"JW Wheless","year":"2010","unstructured":"Wheless JW, Vazquez B. Rufinamide: a novel broad-spectrum antiepileptic drug. Epilepsy Curr. 2010;10(1):1\u20136. https:\/\/doi.org\/10.1111\/j.1535-7511.2009.01336.x.","journal-title":"Epilepsy Curr"},{"issue":"11","key":"1691_CR73","doi-asserted-by":"publisher","first-page":"813","DOI":"10.2165\/00003088-200241110-00003","volume":"41","author":"U Christians","year":"2002","unstructured":"Christians U, Jacobsen W, Benet LZ, Lampen A. Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmacokinet. 2002;41(11):813\u201351. https:\/\/doi.org\/10.2165\/00003088-200241110-00003.","journal-title":"Clin Pharmacokinet"},{"key":"1691_CR74","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.01031","volume":"10","author":"RA Weersink","year":"2019","unstructured":"Weersink RA, Timmermans L, Monster-Simons MH, Mol PGM, Metselaar HJ, Borgsteede SD, et al. Evaluation of information in summaries of product characteristics (SmPCs) on the use of a medicine in patients with hepatic impairment. Front Pharmacol. 2019;10:1031. https:\/\/doi.org\/10.3389\/fphar.2019.01031.","journal-title":"Front Pharmacol"},{"issue":"4","key":"1691_CR75","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1002\/epi4.12959","volume":"9","author":"JJ Rodr\u00edguez-Uranga","year":"2024","unstructured":"Rodr\u00edguez-Uranga JJ, S\u00e1nchez-Caro JM, Hariramani Ramchandani R. Treatment simplification to optimize cenobamate effectiveness and tolerability: a real-world retrospective study in Spain. Epilepsia Open. 2024;9(4):1345\u201356. https:\/\/doi.org\/10.1002\/epi4.12959.","journal-title":"Epilepsia Open"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01691-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-026-01691-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01691-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T16:23:10Z","timestamp":1788538990000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-026-01691-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":75,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1691"],"URL":"https:\/\/doi.org\/10.1007\/s40262-026-01691-9","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]},"assertion":[{"value":"24 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.","order":1,"name":"Ethics","label":"Funding","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This study is a narrative review of published literature and regulatory documents and did not involve human participants, human data, or human tissue.","order":3,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Consent to Publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All data analyzed in this review were derived from publicly available sources, including US Food and Drug Administration (FDA) Prescribing Information, European Medicines Agency (EMA) Summaries of Product Characteristics, and published pharmacokinetic studies. No original datasets were generated during this study.","order":6,"name":"Ethics","label":"Data Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":7,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Shuai Wang had the idea for the review, performed the literature search and data extraction, drafted the manuscript, and prepared all tables. Jingheng Wu conceptualized the study, provided critical supervision throughout the project, and critically revised the manuscript for important intellectual content. Miaomiao Li assisted with data extraction and verification of regulatory labeling information and reviewed the manuscript for accuracy. All authors read and approved the final manuscript.","order":8,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}